Savin R C
Department of Dermatology, Yale University School of Medicine, CT.
J Am Acad Dermatol. 1990 Oct;23(4 Pt 2):786-9. doi: 10.1016/0190-9622(90)70289-t.
Twenty-seven patients with chronic tinea pedis, athlete's foot type, were enrolled in a randomized, double-blind trial of topical treatment with terbinafine 1% cream versus its vehicle (placebo). Patients were examined weekly during 4 weeks of twice-daily treatment and at follow-up 2 weeks after the conclusion of therapy. No adverse events were reported in either treatment group. Drug efficacy was evaluated in 22 patients, of whom nine (41%) were treated with terbinafine and 13 (59%) with placebo. Analysis of combined mycologic and clinical results showed that terbinafine was significantly more effective than placebo at the end of therapy (78% vs zero) and at the 2-week follow-up (89% vs zero) (p less than or equal to 0.001 at both intervals.
27例慢性足癣（运动员脚型）患者参加了一项随机双盲试验，比较1%特比萘芬乳膏与其赋形剂（安慰剂）的局部治疗效果。在每日两次治疗的4周期间，患者每周接受检查，并在治疗结束后2周进行随访。两个治疗组均未报告不良事件。对22例患者进行了药物疗效评估，其中9例（41%）接受特比萘芬治疗，13例（59%）接受安慰剂治疗。综合真菌学和临床结果分析显示，在治疗结束时（78% vs 0）和2周随访时（89% vs 0），特比萘芬明显比安慰剂更有效（两个时间点p均≤0.001）。
